Chong Kun Dang speeds up dyslipidemia drug development
By Son, Hyung Min | translator Alice Kang
24.11.05 05:02:52
가나다라
0
CKD-508, approved to initiate Phase 1 trial in the U.S.… 2nd-generation CETP inhibitor
Development started in 2014... second trial after the UK trial
5 clinical trials on of synthetic new drugs…also develops treatments for rare diseases and liver diseases
Chong Kun Dang is accelerating the development of new drugs for dyslipidemia. The company has received approval to initiate a second global clinical trial in 10 years for its new drug candidate 'CKD-508' since the company began its research in 2014.
According to industry sources on the 4th, Chong Kun Dang recently received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial on its dyslipidemia drug candidate, 'CKD-508'.
Through the clinical trial, Chong Kun Dang plans to verify the safety and lipid-improving effect of CKD-508 and explore the optimal dose for its future Phase 2 trial.
CKD-508 is a second-generation dr
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)